C.E. Traverso

422 total citations
10 papers, 240 citations indexed

About

C.E. Traverso is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Rheumatology. According to data from OpenAlex, C.E. Traverso has authored 10 papers receiving a total of 240 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Ophthalmology, 5 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Rheumatology. Recurrent topics in C.E. Traverso's work include Glaucoma and retinal disorders (5 papers), Retinal Imaging and Analysis (2 papers) and Systemic Lupus Erythematosus Research (2 papers). C.E. Traverso is often cited by papers focused on Glaucoma and retinal disorders (5 papers), Retinal Imaging and Analysis (2 papers) and Systemic Lupus Erythematosus Research (2 papers). C.E. Traverso collaborates with scholars based in Italy, United States and France. C.E. Traverso's co-authors include Karim F. Tomey, Aldo Vagge, Lorenzo Ferro Desideri, G. Calabria, Carlo Alberto Cutolo, Massimo Nicolò, Riccardo Scotto, Michele Iester, John A. Glaspy and Laura Bonzano and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Ophthalmology and European Journal of Ophthalmology.

In The Last Decade

C.E. Traverso

10 papers receiving 226 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C.E. Traverso Italy	4	222	150	33	14	14	10	240
Amanda K. Bicket United States	10	264 1.2×	183 1.2×	39 1.2×	15 1.1×	11 0.8×	26	286
Maurice W. Tuck United Kingdom	9	342 1.5×	259 1.7×	28 0.8×	18 1.3×	15 1.1×	15	362
Ki Bang Uhm South Korea	11	280 1.3×	218 1.5×	26 0.8×	17 1.2×	7 0.5×	32	294
Gavin Tan Singapore	9	311 1.4×	251 1.7×	28 0.8×	33 2.4×	16 1.1×	25	351
Susana Duch Spain	9	316 1.4×	235 1.6×	62 1.9×	38 2.7×	7 0.5×	21	350
Jimmy Shiu Ming Lai Hong Kong	7	244 1.1×	173 1.2×	37 1.1×	23 1.6×	8 0.6×	12	263
Ricardo Augusto Paletta Guedes Brazil	10	305 1.4×	221 1.5×	36 1.1×	29 2.1×	18 1.3×	48	341
Yuan Shi Singapore	9	217 1.0×	171 1.1×	13 0.4×	35 2.5×	13 0.9×	11	249
Connie Chou United States	5	374 1.7×	156 1.0×	75 2.3×	7 0.5×	13 0.9×	8	398
Daniel Byles United Kingdom	7	229 1.0×	96 0.6×	30 0.9×	32 2.3×	9 0.6×	13	245

Countries citing papers authored by C.E. Traverso

Since Specialization

Citations

This map shows the geographic impact of C.E. Traverso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.E. Traverso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.E. Traverso more than expected).

Fields of papers citing papers by C.E. Traverso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.E. Traverso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.E. Traverso. The network helps show where C.E. Traverso may publish in the future.

Co-authorship network of co-authors of C.E. Traverso

This figure shows the co-authorship network connecting the top 25 collaborators of C.E. Traverso. A scholar is included among the top collaborators of C.E. Traverso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.E. Traverso. C.E. Traverso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Lipsyc-Sharf, Marla, C.E. Traverso, Adam Dugan, et al.. (2025). Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study.. Journal of Clinical Oncology. 43(16_suppl). 1041–1041. 1 indexed citations

2.

Viola, P., et al.. (2021). Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: ageneral overview. Drugs of today. 57(11). 689–689. 3 indexed citations

3.

Desideri, Lorenzo Ferro, Carlo Alberto Cutolo, C.E. Traverso, & Massimo Nicolò. (2021). Razumab -- the role of biosimilars for the treatment of retinaldiseases. Drugs of today. 57(8). 499–499. 2 indexed citations

4.

Desideri, Lorenzo Ferro, Aldo Vagge, Massimo Nicolò, & C.E. Traverso. (2021). An overview of gene therapies in the pipeline for ocular disorders. Drugs of the Future. 46(5). 383–383. 1 indexed citations

5.

Iester, Michele, et al.. (2008). Rarebit Perimetry and Frequency Doubling Technology in Patients with Ocular Hypertension. European Journal of Ophthalmology. 18(2). 205–211. 4 indexed citations

6.

Roccatagliata, Luca, et al.. (2007). Artefacts of Magnetic Resonance Imaging in Patients Implanted With a Stainless Steel Glaucoma Drainage Micro-Device. 48(13). 483–483. 2 indexed citations

7.

Traverso, C.E.. (2005). Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. British Journal of Ophthalmology. 89(10). 1245–1249. 191 indexed citations

8.

Kelly, Simon P., C.E. Traverso, J.P. Renard, et al.. (2003). A Multi-National, Retrospective Study of Resource Utilization Associated with Glaucoma disease Progression in Europe. 44(13). 61–61. 1 indexed citations

9.

Iester, Michele, et al.. (2002). Reproducibility of a new technique to analyse retinal blood flow. Acta Ophthalmologica Scandinavica. 80(s236). 51–52. 1 indexed citations

10.

Tomey, Karim F., et al.. (1987). Neodymium-YAG Laser Iridotomy in the Treatment and Prevention of Angle Closure Glaucoma. Archives of Ophthalmology. 105(4). 476–481. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact